BACKGROUND: Use of dietary supplements (DS) is common in the United States; however little is known about the use of DS specifically in hospitalized patients.
BACKGROUND
Use of dietary supplements (DS) in the United States is widespread with nearly 20% of Americans reporting use of DS within the past 12 months 1, 2 . Unfortunately, growth in use of DS has not been paralleled by increased communication between patients and physicians addressing this topic 3 . The literature documenting trends in the utilization of DS and disclosure of use to physicians has been predominantly in the outpatient setting [4] [5] [6] . Although the use of DS is more common among patients who have been hospitalized within the past 12 months, specifics about use of DS in these patients are lacking 1 . The purpose of this pilot study was to characterize DS use by hospitalized patients, evaluate patient-physician communication about use of DS during the hospital admission process, and document patients' attitudes and expectations about DS use while hospitalized.
METHODS
Subjects. Eligible patients admitted by internal medicine house staff residents to the medicine and geriatric services at the University of North Carolina (UNC) Medical Center were invited to participate in the survey. Eligibility criteria included: age ≥18 years, medically stable (i.e., not in an ICU or being evaluated for ICU admission), cognitively intact, and conversant in English or Spanish. Patients in isolation were excluded. Approval for the study was granted by the UNC IRB. 
RESULTS
Demographic Information. Of 177 patients admitted over a six week period, 23% were unavailable for eligibility assessment, 29% did not meet eligibility criteria and 14% refused participation. Sixty patients were evaluated for DS use. Table 1 highlights demographic characteristics.
DS Use. At admission, 78.3% (n=47) of patients reported use of DS and 52% used non-vitamin/non-mineral (NV/NM) DS (n = 31). Excluding DS also used as foods (green tea, acidophilus yogurt, protein powder), 48.9% reported using NV/NMDS. The use of a wide variety of DS was reported as indicated in Table 2 .
Mean number of DS used was 2.6 ± 2.4 (range 0-11). Reported DS use did not vary significantly by gender (women 71.4%; men 84.6%). Caucasians were more likely to report use of DS (93.1%) than non-Caucasians (African-Americans 69.6%; Hispanics 50%).
Patient-physician Communication. Seventy-five percent (n=45) of patients reported that no physician inquired about DS use at the time of admission and 5% (n=3) were unsure. Retrospective review of admission documents revealed that 80% of patients' charts had no documentation to support that the admitting physician had inquired about DS use.
Of those using DS, 74% did not inform the admitting physician about their use of DS. Rationales for not doing so included: 1) patient felt that it was not important to report DS use (55.9%); 2) admitting physician did not ask (20.6%); 3) patient thought that the DS use was already recorded in the chart and therefore assumed the admitting physician was aware of DS use (17.6%); and 4) patient felt that the admitting physician did not care about DS use (5.9%). Nine percent of patients reported telling the admitting physician about their DS despite not specifically being asked.
Attitudes about Continued Use of DS while Hospitalized. Of those using DS, 86% stated that they would not be concerned about stopping their DS temporarily while hospitalized, if requested by their physician, with 55% stating that they would absolutely follow their physicians' recommendations regarding DS use while hospitalized. However, 13% stated they did not think it was dangerous to continue their DS while hospitalized despite medical advice.
Finally, when asked about their plans for discussing DS use with the discharging physician, 45% of patients taking DS did not plan on discussing their DS use, 10% said they probably would discuss DS use, 26% said they would definitely discuss their DS, use and 19% said they would wait and discuss their DS use with their primary care provider after discharge.
DISCUSSION
To our knowledge this is the first published report documenting DS use in US hospitalized patients. We demonstrate that DS use is common in hospitalized patients with nearly 80% of 6 . One possible explanation is sampling bias, since 14% of the eligible patients refused to participate in the survey for unknown reasons. Presumably some refused because they were not using DS, which could partially explain our higher reported rates of DS use. Consistent with outpatient studies of DS use, we found that most patients do not inform healthcare providers about their DS use. The main reason for non-disclosure was that patients believed their DS use was unimportant to the healthcare team. Importantly, we discovered that the majority of patients were never asked by the admitting resident physician about DS use. This is similar to findings from Israel where only 6% of patients were specifically asked about DS use during the admission process 9 . Their lack of inquiry about DS use suggests that resident physicians may not be adequately trained to recognize the serious potential for adverse dietary supplement-drug interactions. During a hospitalization, patients are a captive audience, and this is an opportune time for education 10 .
Misconceptions about DS are common and most patients are interested in additional information about DS use, therefore we view a hospitalization as a valuable educational opportunity for discussion about DS use. Following an admission to the hospital, often new medications are included on the patient's discharge medication list. We show that very few patients definitely intended to discuss their DS use with the heath care team prior to discharge. If the physician is unaware of patients' plans for resumption of DS upon discharge, the potential exists for DS-drug interaction that could contribute to additional morbidity and possibly mortality. The majority of patients were not concerned about temporary discontinuation of their DS while hospitalized; however a small, but significant percentage of patients (13%) saw no harm in continuing to use their DS while in the hospital despite medical advice. As reliance upon DS for perceived health enhancement continues to escalate in the US, hospital staff and administration are confronted with challenges related to DS use in hospitalized patients. The Joint Commission of Health Care Organizations (JCHCO) has mandated that health-care providers become more aware of patients' use of DS in the hospital 11 . Under JCHCO directives, the use of DS in the hospital must be governed by policies that regulate nonprescription medications brought from home and medical staff approval is required prior to allowing a patient to use any DS brought from home. Limitations include small sample size and the potential for recall bias. Additionally, generalizability is limited given our single, tertiary referral center location and by the fact that only patients admitted by internal medicine residents to the general medicine and geriatric services were included in the our analyses. Typically the general medicine and geriatric services at UNC admit patients with a variety of medical problems; however, we acknowledge that a large proportion of the patients surveyed had gastrointestinal (GI) complaints. At the time this pilot study was conducted, there was no specific GI specialty service at UNC, which potentially explains this sampling bias.
Our findings suggest that: 1) use of DS in hospitalized patients is common, 2) communication about DS use between admitting resident physicians and patients is limited, and 3) although most patients were not concerned about discontinuing their DS while hospitalized, 13% of patients reported they saw no harm in continuing their DS despite medical advice to discontinue the DS during hospitalization. Further research is needed to explore the generalizability of our findings, as well as to explore strategies for improving physician-patient communication about DS use in-hospital, and for improving hospital staff education about DS indications and contraindications.
